Meckler Jeffrey A 4

What Happened

• Jeffrey A. Meckler, CEO of Indaptus Therapeutics (INDP), recorded matched derivative dispositions and acquisitions on Feb 11, 2026: dispositions of 3,033; 1,519; and 12,136 derivative units and contemporaneous acquisitions of the same amounts — a total of 16,688 derivative securities disposed and 16,688 acquired. Transaction entries are coded as D (Disposition to issuer) and A (Grant/award or other acquisition). No per‑share dollar amounts or cash totals are reported (price = N/A).

Key Details

• Transaction date: February 11, 2026. Form 4 filed Feb 13, 2026 (timely filing).
• Reported moves: three paired D (disposed to issuer) and A (acquired) entries for 3,033; 1,519; and 12,136 derivative units (total 16,688).
• Price/value: N/A in the filing; these are derivative instruments (warrants), not open‑market trades in common stock.
• Footnote: The board approved a unilateral reduction in the per‑share exercise price of the warrants to $1.75 effective Feb 11, 2026 (F1). All other warrant terms unchanged.
• Reverse split: A 1‑for‑28 reverse stock split effective June 26, 2025 was applied to all amounts in the filing.
• Shares owned after transaction: not specified in the provided filing extract.

Context

• These entries reflect derivative activity (warrants) tied to a corporate repricing rather than a typical buy or sale of common shares. The pattern—disposition to the issuer paired with an acquisition—appears to document surrender/reattribution around the board‑approved warrant price adjustment. No cash proceeds or open‑market purchases/sales of common stock are reported, so this should be viewed as a corporate restructuring of derivative holdings rather than a direct insider market buy/sell.